Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Neoantigen DNA Vaccine and Retifanlimab in Newly Diagnosed Unmethylated Glioblastoma
NCT05743595Phase 1Active, not recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Oct 2023
- Primary completion
- Apr 2026
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of polyepitope neoantigen dna vaccine in glioblastoma (GBM) (2 cohorts), sponsored by Washington University School of Medicine. Primary endpoint: Dose-Limiting Toxicity rate. Started Oct 2023; status: active, not recruiting.
02
Drugs
polyepitope neoantigen dna vaccine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05743595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05743595.